Results 101 to 110 of about 72,161 (311)

Molecular imaging of endothelial activation and mineralization in a mouse model of accelerated atherosclerosis

EJNMMI Research, 2019
Purpose Preclinical imaging of endothelial activation and mineralization using both positron emission tomography (PET) and magnetic resonance (MR) remains scarce.
Guillaume Rucher, Lucie Cameliere, Jihene Fendri, Antoine Anfray, Ahmed Abbas, Saïd Kamel, Quentin Dupas, Nicolas Delcroix, Ludovic Berger, Alain Manrique, on behalf of the STOP-AS investigators   +10 more
doaj   +1 more source

Development of geriatric medicines: to GIP or not to GIP? [PDF]

, 2014
The elderly population represents a heterogeneous group of patients, which show co-morbidities and is often poly-medicated. Although geriatric patients form the main users of medicines, this group is underrepresented in clinical trials.
Bracke, Nathalie, De Spiegeleer, Bart, Stalmans, Sofie   +2 more
core  

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials

Obesity, EarlyView.
ABSTRACT Objective This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity. Methods A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults ...
Lucas Sabatella, Patricia M. Ortega, Víctor Valentí Azcárate, Fernando Rotellar Sastre, Adriana Uriz Pagola, Ahmed Ahmed, Sanjay Purkayastha, Carlota Tuero Ojanguren, Nuria Blanco Asensio, Manuel F. Landecho   +9 more
wiley   +1 more source

Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: An association analysis of polymorphisms and bone in young and elderly women

Bone Reports, 2016
Introduction: The gastro-intestinal hormone glucose-dependent insulinotropic polypeptide (GIP) potentiates glucose-induced insulin secretion, with bone anabolic effects through GIP receptor (GIPR) in animal models.
Gaurav Garg, Fiona E. McGuigan, Jitender Kumar, Holger Luthman, Valeriya Lyssenko, Kristina Akesson   +5 more
doaj   +1 more source

The antecedents of green innovation performance: A model of learning and capabilities [PDF]

, 2016
Environmental management and green practices have a narrow linkage with fi rm innovativeness. Companies that are pioneersin green innovation strategies might reach and sustain competitive advantages. Thus, successful green innovation performance (GIP)
Albort-Morant, Gema, Cepeda-Carrión, Gabriel, Leal Millán, Antonio Genaro   +2 more
core   +1 more source

Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition

Journal of Clinical Investigation, 2019
Nutrient excess, a major driver of obesity, diminishes hypothalamic responses to exogenously administered leptin, a critical hormone of energy balance.
Kentaro Kaneko, Yukiko Fu, Hsiao-Yun Lin, E. Cordonier, Qianxing Mo, Yong Gao, Ting Yao, Jacqueline Naylor, Victor G. Howard, Kenji Saito, Pingwen Xu, Siyu S Chen, Miao-Hsueh Chen, Yong Xu, K. Williams, P. Ravn, M. Fukuda   +16 more
semanticscholar   +1 more source

Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis

Nutrients, 2020
Nutrient excess enhances glucose-dependent insulinotropic polypeptide (GIP) secretion, which may in turn contribute to the development of liver steatosis.
J. Góralska, U. Raźny, A. Polus, Agnieszka Dziewońska, A. Gruca, A. Zdzienicka, A. Dembińska-kieć, B. Solnica, A. Micek, M. Kapusta, Krystyna Słowińska-Solnica, M. Malczewska-Malec   +11 more
semanticscholar   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Obesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays, Phillip Toth, Naim Alkhouri, John Pullman, Bradley Freilich, Joel Neutel, Summer Ji, Scott Stubbe, Parke Hedges, Brian Lian   +9 more
wiley   +1 more source

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

Obesity, EarlyView.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden, Maria A. Oquendo, Robert F. Kushner, Dachuang Cao, Chrisanthi A. Karanikas, Afton Kechter, Madhumita A. Murphy   +6 more
wiley   +1 more source